<DOC>
	<DOCNO>NCT00369434</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety 100 mg 150 mg DVS SR , extend release form desvenlafaxine succinate , comparison placebo treatment Vasomotor Symptoms ( VMS ) associate menopause population postmenopausal woman .</brief_summary>
	<brief_title>Study Safety Efficacy Desvenlafaxine Succinate Vasomotor Symptoms Postmenopausal Women</brief_title>
	<detailed_description>To assess efficacy safety 100 mg 150 mg DVS SR comparison placebo treatment moderate severe VMS associate menopause , well additional outcome indicator sleep disruption , overall climacteric symptom , mood change , somatic symptom , overall satisfaction DVS SR postmenopausal woman .</detailed_description>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Generally healthy , postmenopausal woman seek treatment hot flush Body Mass Index ( BMI ) less equal 40 kg/m2 Other inclusion apply . Hypersensitivity Venlafaxine Myocardial infarction and/or unstable angina within 6 month screen History seizure disorder Other exclusion apply .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>